



## MONOGRAPH

# METARAMINOL

Scope (Staff):	Medical, Pharmacy, Nursing, Anaesthetic Technicians
Scope (Area):	Emergency Department, Paediatric Critical Care, Theatres

### Child Safe Organisation Statement of Commitment

CAHS commits to being a child safe organisation by applying the National Principles for Child Safe Organisations. This is a commitment to a strong culture supported by robust policies and procedures to reduce the likelihood of harm to children and young people.

This document should be read in conjunction with this [DISCLAIMER](#)

## ! HIGH RISK MEDICINE !

### QUICKLINKS

[Dosage/Dosage  
Adjustments](#)

[Administration](#)

[Compatibility](#)

[Monitoring](#)

### DRUG CLASS

Sympathomimetic.

Metaraminol is a [High Risk Medicine](#).

### INDICATIONS AND RESTRICTIONS

- Acute hypotensive state.<sup>1</sup>
- Adjunctive treatment of hypotension.<sup>1</sup>

### CONTRAINDICATIONS

Hypersensitivity to metaraminol or any component of the formulation (contains sodium metabisulfite).<sup>1</sup>

### PRECAUTIONS

- Correct hypovolaemia before using metaraminol.<sup>2</sup>
- Liver cirrhosis.<sup>2</sup>
- Concurrent use with digoxin – risk of ectopic arrhythmias.<sup>1</sup>
- Concurrent use with monoamine oxidase inhibitor or tricyclic antidepressants – potential increase in sympathomimetic effects.<sup>1</sup>

- Heart disease, hypertension, thyroid disease, diabetes mellitus – metaraminol causes vasoconstriction.<sup>1</sup>

## FORMULATIONS

Listed below are products available at PCH, other formulations may be available, check with pharmacy if required:

- 10 mg/mL ampoule.

Imprest location: [Formulary One](#)

## DOSAGE, DOSAGE ADJUSTMENTS AND ADMINISTRATION

Extravasation may cause tissue necrosis. Administer via large peripheral vein or a Central Venous Access Device (CVAD). Monitor for signs of extravasation.<sup>3</sup>

### Child (≥ 4 weeks – 18 years)

#### IV injection<sup>3, 4</sup>:

- 10 micrograms/kg/dose (max 500 micrograms).
  - In emergency situations, administer as a push injection.
  - Repeat every 2 to 5 minutes or commence IV continuous infusion if required.
- Dilute 10 mg metaraminol to 100 mL with sodium chloride 0.9% to make 100 micrograms/mL solution.

#### IV continuous infusion<sup>3, 4</sup>:

- 0.05 – 0.5 micrograms/kg/minute, titrate to effect. Doses of up to 5 micrograms/kg/minute may be required.

Patient's Weight	Concentration	Notes
<b>10 kg or less</b>	1 mg in 30 mL (33 microg/mL)	In a 3 kg patient 0.05 microg/kg/min = 0.3 mL/hour
<b>Above 10 kg</b>	10 mg in 50 mL (200 microg/mL)	In a 20 kg patient, 0.05 microg/kg/min = 0.3 mL/hour

- Administration via CVAD is preferred.
- Do not cease continuous infusion abruptly, wean gradually.

#### IM injection<sup>4</sup>:

- Not recommended but may be considered in an emergency, when IV access is not available.
- 0.1 mg/kg/dose (100 micrograms/kg/dose).

#### Renal impairment:

- No dosage adjustment necessary.<sup>4</sup>

#### Hepatic impairment:

- No dosage adjustment necessary. Use with caution in patients with cirrhosis.<sup>2</sup>

## COMPATIBILITY (LIST IS NOT EXHAUSTIVE)

### Compatible fluids:

Glucose 5% (preferred), sodium chloride 0.9%, Ringer's, Hartmann's solution/compound sodium lactate (except Torbay® brand).<sup>3</sup>

### Compatible at Y-site:

No data for drug compatibility.<sup>4</sup> Plasma-Lyte 148 compatible via Y-site.<sup>3</sup>

*Only commonly used drugs are listed below. This is not a complete list of incompatible drugs.*

*[Compatibilities of IV drugs](#) must be checked when two or more drugs are given concurrently.*

### INCOMPATIBLE drugs:

Atropine, benzylpenicillin, furosemide, thiopental sodium.<sup>3</sup>

## MONITORING

Continuous cardiac monitoring.<sup>3</sup>

## ADVERSE EFFECTS<sup>2</sup>

**Common:** Headache, hypertension.

**Infrequent:** Arrhythmia, bradycardia, peripheral ischaemia.

**Rare:** Abscess and necrosis caused by extravasation injury.

## STORAGE

Store below 25°C. Protect from light.<sup>3</sup>

## INTERACTIONS

This medication may interact with other medications; consult PCH approved references (e.g. [Clinical Pharmacology](#)), a clinical pharmacist or PCH Medicines Information Service on extension 63546 for more information.

*\*\*Please note: The information contained in this guideline is to assist with the preparation and administration of **metaraminol**. Any variations to the doses recommended should be clarified with the prescriber prior to administration\*\**



## Related CAHS internal policies, procedures and guidelines

[CAHS Policy Manual: High Risk Medicines Policy](#)

## References

1. Newth N. AusDI: product information. 2024 [Available from: <https://ausdi-hcn-com-au.pklibresources.health.wa.gov.au/quickSearch.hcn>].
2. Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists., Pharmaceutical Society of Australia., The Royal Australian College of General Practitioners. Australian medicines handbook, 2024. Adelaide SA: Australian Medicines Handbook;
3. Burridge N, Collard N, Symons K, Society of Hospital Pharmacists of Australia. Australian injectable drugs handbook. Eighth edition. ed. Collingwood, Vic.: The Society of Hospital Pharmacist of Australia; 2024 [cited. Available from: [http://aidh.hcn.com.au.pklibresources.health.wa.gov.au/browse/about\\_aidh](http://aidh.hcn.com.au.pklibresources.health.wa.gov.au/browse/about_aidh)].
4. Micromedex®. Greenwood Village, Colorado, USA: Truven Health Analytics; 2024 [Available from: <http://www-micromedexsolutions-com.pklibresources.health.wa.gov.au/>].

This document can be made available in alternative formats on request for a person with a disability.

<b>File Path:</b>	W:\Safety & Quality\CAHS\CLOVERS MEDICAL Pharmacy\Procedures Protocols and Guidelines\Medication Monographs\_Word\PCH.MED.Metaraminol.docx		
<b>Document Owner:</b>	Chief Pharmacist		
<b>Reviewer / Team:</b>	Senior Pharmacist, PCC HoD, ED HoD, Consultant Anaesthetist, PCC CNS.		
<b>Date First Issued:</b>	Sep 2015	<b>Last Reviewed:</b>	Feb 2024
<b>Amendment Dates:</b>	Jun 2020, Feb 2024, Oct 2024, Oct 2025	<b>Next Review Date:</b>	Feb 2027
<b>Approved by:</b>	PCH&N Medication Safety Committee	<b>Date:</b>	Oct 2025
<b>Endorsed by:</b>	CAHS Drug & Therapeutics Committee	<b>Date:</b>	Nov 2025
<b>Standards Applicable:</b>	NSQHS Standards:   NSMHS: N/A Child Safe Standards: N/A		

Printed or personally saved electronic copies of this document are considered uncontrolled



Healthy kids, healthy communities

Compassion

Excellence

Collaboration

Accountability

Equity

Respect

Neonatology | Community Health | Mental Health | Perth Children's Hospital